CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 128,853	$ 181,468	$ 34,597
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation	514	419	416
Intangible amortization	23,845	22,966	18,424
Acquired in-process research & development (IPR&D) expense	2,260
Stock-based and employee stock purchase compensation expense	31,705	26,173	15,659
Stock appreciation rights market adjustment	(499)	732	446
Debt issuance costs amortization	2,274	1,663	2,238
Deferred taxes	(13,419)	(85,943)
Amortization of premiums and accretion of discounts on Investment securities	(2,715)	(432)
Loss on debt extinguishment	9,766		26,146
Other non-cash expenses	1,768	1,526
Change in operating assets and liabilities:
Trade receivables	(19,400)	(19,897)	(12,667)
Inventory	(1,066)	135	(609)
Prepaid expenses and other assets	74	(7,548)	(1,655)
Trade payables	8,949	2,785	(1,555)
Accrued expenses and other current liabilities	46,479	20,570	17,263
Other non-current liabilities	(1)	(151)	(146)
Net cash provided by operating activities	219,387	144,466	98,557
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities	(127,469)	(110,729)
Proceeds from maturities and sales of investment securities	118,309	9,069
Purchase of property and equipment	(312)	(172)	(298)
Acquisition of Zynerba Pharmaceuticals, Inc., net of cash acquired	(36,967)
Milestone payments		(40,000)	(100,000)
Net cash used in investing activities	(46,439)	(141,832)	(100,298)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			30,000
Common stock issuance costs			(300)
Proceeds from issuance of debt	200,000		200,000
Debt issuance costs	(2,997)		(9,152)
Extinguishment of debt	(196,500)		(200,000)
Extinguishment of debt exit fees	(5,846)		(22,000)
Principal repayment of long term debt	(4,750)	(2,000)	(500)
Repurchase of common stock	(100,000)
Payments of employee withholding taxes related to stock-based awards	(514)
Proceeds from exercised options	5,055	8,841	9,371
Net cash (used in) provided by financing activities	(105,552)	6,841	7,419
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	67,396	9,475	5,678
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period	244,534	235,059	229,381
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period	311,930	244,534	235,059
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest	20,051	16,364	19,830
Cash paid during the year for taxes	$ 48,233	$ 12,645	$ 2,875